NCT03524820 is a Phase 2 clinical trial of Cetuximab in Cancer of Colon, sponsored by Hadassah Medical Organization.

Who is sponsoring NCT03524820?

NCT03524820 is sponsored by Hadassah Medical Organization.

What drugs are being tested in NCT03524820?

Interventions in NCT03524820: Cetuximab.

What condition does NCT03524820 study?

NCT03524820 studies Cancer of Colon.

Is NCT03524820 still recruiting?

NCT03524820 is currently terminated. Last updated 4 August 2022.

Last reviewed 2022-08-04 · How we verify

NCT03524820

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Terminated Phase 2 Last updated 4 August 2022

What this trial tests

Phase 2 trial testing Cetuximab in Cancer of Colon in 3 participants. Terminated before completion.

Timeline

17 October 2017

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Hadassah Medical Organization
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	17 October 2017
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Israel

Drugs / interventions tested

Cetuximab (cetuximab) — full drug profile →

Conditions studied

Cancer of Colon — all drugs for Cancer of Colon →

Sponsor

Hadassah Medical Organization — full company profile →

Who can join

Adults 18 to 120, any sex, with Cancer of Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is intended to check the benefit of treatment with cetuximab in metastatic colorectal cancer patients with wild type RAS as third line treatment. The advantage to the patients is unclear. This study will look if mutations in patients' blood area predictive marker for progression free time (FPT) in metastatic colorectal cancer patients treated with third line cetuximab. A predictive marker for FPT metastatic colorectal cancer patients treated with third line cetuximab will enable a reduction in the number of treated patients. Treatment only of patients with a positive marker is expected to prevent inefficient treatment which will reduce suffering for the patients and reduce unnecessary medical treatment.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer.
Martini G, Dienstmann R, Ros J, Baraibar I, et al · · 2020 · cited 36× · PMID 32782486 · DOI 10.1177/1758835920936089
Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer.
Ciardiello D, Martini G, Famiglietti V, Napolitano S, et al · · 2021 · cited 30× · PMID 33920531 · DOI 10.3390/cancers13081941
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives.
Personeni N, Smiroldo V, Giunta EF, Prete MG, et al · · 2021 · cited 17× · PMID 34572729 · DOI 10.3390/cancers13184506
New developments in targeted therapy for metastatic colorectal cancer.
Wong AHN, Ma B, Lui RN. · · 2023 · cited 13× · PMID 36687386 · DOI 10.1177/17588359221148540
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> 2021, <i>13</i>, 1941.
Ciardiello D, Martini G, Famiglietti V, Napolitano S, et al · · 2022 · cited 2× · PMID 36011056 · DOI 10.3390/cancers14163900

Verify or expand the search:

Other trials of Cetuximab

Trials testing the same drug.

NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT06418724 — Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT07411599 — Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out · Phase 1, PHASE2 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting

Other recruiting trials for Cancer of Colon

Currently open trials in the same condition.

NCT05163028 — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations · Phase 1 · active not recruiting
NCT05179824 — Tempus Priority Study: A Pan-tumor Observational Study · active not recruiting
NCT04259398 — Anesthesia and Cancer Study: Colon Cancer · NA · active not recruiting

Other Hadassah Medical Organization trials

Trials by the same sponsor.

NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03524820 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
Last refreshed: 4 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03524820.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing